Neppe V M
J Clin Psychiatry. 1983 Sep;44(9):326-31.
A 15-week double-blind, randomized, within-patient design was used to assess carbamazepine versus placebo as adjunctive treatment in chronic hospitalized psychiatric inpatients (predominantly schizophrenic) with EEG temporal lobe abnormalities but no clinical evidence of epilepsy. A statistically significant improvement on carbamazepine was found on all clinical rating measures used (Overall Clinical Rating, Brief Psychiatric Rating Scale, and Global Assessment). The results also appeared to be clinically significant.
采用一项为期15周的双盲、随机、患者内设计，评估卡马西平与安慰剂作为辅助治疗手段，用于患有脑电图颞叶异常但无癫痫临床证据的慢性住院精神科患者（主要为精神分裂症患者）的疗效。在所使用的所有临床评定量表（总体临床评定量表、简明精神病评定量表和综合评定量表）上，卡马西平组均有统计学意义上的显著改善。结果在临床上似乎也具有显著意义。
